Risk factors for disease generalization in acetylcholine receptor antibody-positive ocular myasthenia: a multicenter retrospective study - Scorecard - MDSpire

Risk factors for disease generalization in acetylcholine receptor antibody-positive ocular myasthenia: a multicenter retrospective study

  • By

  • Lorenzo Verriello

  • Roberto Sartor

  • Fabrizio Bellizzi

  • Chiara Dalla Torre

  • Maria Elena Pessa

  • Marco Belluzzo

  • Alessio Bratina

  • Magda Quagliotto

  • Chiara Rosa Mancinelli

  • Michele Rana

  • Fulvio Pasquin

  • Martina Fabris

  • Giada Pauletto

  • Miriam Isola

  • Maria De Martino

  • Paolo Manganotti

  • Mariarosaria Valente

  • May 25, 2026

  • 0 min

Share

Clinical Scorecard: Identifying Risk Factors for Disease Progression in Ocular Myasthenia Gravis with Acetylcholine Receptor Antibodies: A Multicenter Retrospective Analysis

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with ocular-onset myasthenia gravis positive for anti-AChR antibodies, meeting specific inclusion criteria.
Care Setting

Key Highlights

  • Clarify the implications of the findings regarding predictors.

Guideline-Based Recommendations

Diagnosis

    Management

    • Include specific treatment options such as immunosuppressants and their rationale.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Patients with ocular-onset myasthenia gravis positive for anti-AChR antibodies.

        Acetylcholinesterase inhibitors and corticosteroids are commonly used.

        Clinical Best Practices

        • details

        Related Resources & Content

        Original Source(s)

        Related Content